Background: Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole.
Introduction
Adjuvant endocrine therapy substantially improves the prognosis in patients with hormone receptor-positive breast cancer (BC) [1] . Several trials, such as BIG1-98 and ATAC, have analyzed the efficacy of tamoxifen in comparison with aromatase inhibitors (AIs) in postmenopausal hormone receptor-positive patients and demonstrated a superior effect of AIs on the disease-free survival [2] [3] [4] [5] , as well as on the overall survival in some trials [1, 6] .
Patients' adherence to the therapy is important for ensuring treatment efficacy [7, 8] . It has been reported that 50% of patients discontinue treatment with tamoxifen or an AI within 3 years [9] . AIs are known to induce musculoskeletal and climacteric side-effects, which have been identified as reasons for nonadherence [2, 3, [10] [11] [12] . Several studies have analyzed risk factors for nonadherence in women receiving AIs and have identified possible predictive factors [13] [14] [15] [16] [17] . As nonadherence appears to have an effect on the prognosis [7, 14] and only a few studies have investigated predictive factors for it, new insights might help in effectively providing special care in relation to treatment and toxicities in a specific population of patients.
Since terminology varies [7, 18, 19] , which in turn leads to difficulties in comparing and discussing study results, in this analysis, the term 'adherence' is used as an overarching term for both, compliance (medication intake according to prescribed frequency and dose) and persistence (medication intake according to prescribed duration), according to other studies [7, 20] .
The aim of this study was to identify predictive factors for treatment persistence in relation to patient and tumor characteristics which were known at the start of treatment in a prospective, noninterventional study including patients who initially received letrozole therapy in the adjuvant setting.
Methods

Methods-patients
The EvAluate-TM study is a prospective, multicenter, noninterventional, and observational study in which treatment with letrozole is being evaluated in postmenopausal women with hormone receptor-positive BC [21] . Patients received letrozole at 2.5 mg/day, prescribed by their physicians in accordance with drug approval requirements. No other inclusion or exclusion criteria were defined. All of the patients provided written informed consent and all of the relevant ethics committees approved the study.
Methods-materials
Data on patient and tumor characteristics were documented in electronic case report forms. The tumor characteristics noted included stage and previous treatments. Patient information included common epidemiological characteristics, comorbidities, and concomitant medication. There were two pre-specified study visits after 6 and 12 months from the time of inclusion in the study, at which the patients and physicians were asked about treatment adherence. If therapy had been permanently stopped, the reason for ending the treatment and the date had to be documented. In addition, both the physicians and the patients completed prespecified questionnaires about treatment adherence.
Treatment persistence was defined as the time from the start to the end of treatment (TTEOT). In accordance with the study plan, the maximum observation time was 15 months. Patients were censored at the end of the maximum observation period or if applicable beforehand at the date of progression or death.
Methods-statistics
Survival analyses were carried out to identify patients and tumor characteristics that were predictive of TTEOT. A mixed-effects Cox regression model ('full model') was fitted with TTEOT as outcome, study center as random effect, and the following predictors as fixed effects: age at start of therapy (continuous), body mass index (BMI, continuous), Eastern Cooperative Oncology Group grade (ordinal, 0-4), tumor size (ordinal, pT0-pT4), nodal status (pN0 versus pNþ), tumor grade (ordinal, 1-3), HER2 status (negative versus positive), previous neoadjuvant or adjuvant chemotherapy, previous adjuvant radiotherapy, previous or concomitant anti-HER2 therapy (yes versus no), start of letrozole therapy (within 1 year, within 2-5 years, or after 5 years of diagnosis), number of different concomitant medications (integer), and number of known comorbidities (integer). Continuous predictors were used as natural cubic spline functions with three degrees of freedom to describe nonlinear effects. Missing predictor values were imputed as described by Salmen et al. [22] . The variable 'study center' was incorporated into the model as a random effect rather than a fixed effect or stratification variable, because of the large number of centers. The proportional hazards assumptions were checked using the Grambsch and Therneau method.
A global likelihood ratio test was carried out to test whether at least one of the predictors considered was useful. If the result was not significant, no further analyses were carried out, in order to avoid false-positive results. However, if the P value was significant, the Cox model was simplified. The complexity of the continuous predictors was optimized, and a bootstrap-based backward stepwise selection procedure was carried out to identify relevant predictors, as described precisely by Salmen et al. [22] ('final model'). Model performance was evaluated using the HosmerLemeshow v 2 test for survival data [23] , in which a large P value indicates satisfactory calibration. Hazard ratios were calculated using the final model. Interesting findings were illustrated using Kaplan-Meier curves.
Since the significance of predictors does not necessarily imply that those predictors provide a basis for an effective prediction rule for individual patients, the ability of the predictors to distinguish between patients who stopped therapy within 6, 12, and 15 months, respectively, and those patients who did not was assessed using a time-dependent area under the curve (AUC) for survival analyses [24] . Large AUC values might make it possible to search for thresholds for classifying patients as 'high risk' and 'low risk' relative to persistence. To obtain reliable results, each AUC value was estimated by cross-validation, as done previously by Burghaus et al. [25] .
All of the tests were two-sided and a P value of < 0.05 was regarded as statistically significant. Calculations were carried out using the R system for statistical computing (version 3.0.1).
Results
A total of 5045 patients were recruited in the EvAluate-TM study. Patients were excluded in the following hierarchical order: never documented in the database (N ¼ 4), metastatic BC patients (N ¼ 252), patients with insufficient documentation of treatment (N ¼ 394), no follow-up information available (N ¼ 124), and treatment start >7 days before inclusion in the study (N ¼ 330). The final study cohort thus included 3941 patients from 278 study centers. The percentage of missing values for each variable was <1%, with the exception of pN (3.0%). Missing values were imputed as described above.
The patients who were included started letrozole therapy within 1 year of diagnosis (N ¼ 3750), within 2-5 years of diagnosis (N ¼ 163), or after 5 years of diagnosis (N ¼ 28). (Neo)adjuvant chemotherapy had been previously administered in 1479 patients (37.5%) and 1802 (45.7%) had previously received radiotherapy. Adjuvant trastuzumab therapy was started in 3.1% of the patients (N ¼ 123). The patients' characteristics relative to persistence status are provided in Table 1 .
The median observation time was 11 months, during which 607 (15.4%) permanent terminations of treatment were observed. Of these, 67 were due to tumor progression or death of the patient, whereas 540 termination events (13.7%) were for other reasons. The persistence rate was 92.2% after 6 months, 86.9% after 12 months, and 86.3% after 15 months. Further details of persistence rates relative to subgroups are provided in Table 1 .
The main reason for ending treatment was side-effects, as reported in 397 of the 540 events (73.5%). Suboptimal compliance by patients was reported in 6.7% (N ¼ 36), side-effects and suboptimal compliance were reported in 2.6% (N ¼ 14) . In 17.2% (N ¼ 93) the reason for premature end of treatment was unknown.
The global likelihood ratio test showed that together all of the predictors significantly influenced TTEOT (P < 0.001). The selection process identified age, BMI, number of comorbidities, and tumor grade as relevant, resulting in a final Cox regression model that included these predictors. Hazard ratios are provided in Table 2 .
Older patients were more likely to be nonpersistent during the observation period [hazard ratio (HR) 1.02/year, Table 2 ], as well as patients with more comorbidities (HR 1.06 per comorbidity). On the other hand, a higher BMI was associated with a lower rate of non-persistence. A higher tumor grade also indicated a lower likelihood of treatment termination (HR 0.85 per grade). Kaplan-Meier curves are shown in Figure 1A -D.
The full model and the final regression model were well calibrated (P ¼ 0.32 and P ¼ 0.64, Hosmer-Lemeshow test). The models' performance with regard to discrimination was moderate. The cross-validated AUC values for the full model at 6, 12, and 15 months were 0.598, 0.601, and 0.603, respectively. The cross-validated AUC values for the final model were slightly lower, at 0.568, 0.569, and 0.571, implying a certain joint influence of the predictors, which are hardly predictive alone.
Discussion
After 1 year of follow-up, 85% of the patients were still receiving treatment. Persistence was higher in younger patients, patients with a higher BMI, and those with a high tumor grade and fewer comorbidities. It did not appear to be dependent on previous cancer-related treatments such as chemotherapy, radiotherapy, or anti-HER2 therapy.
Several studies have analyzed therapy adherence with endocrine treatment [9, 13-17, 19, 26-30] . Some risk factors for nonadherence have been identified previously. Both older age and younger age have been described as increasing the risk of nonadherence [14, 17, 27] . With regard to comorbidities, some reports have indicated that when present they increase the rate of nonadherence [14, 31] . However, there are also results indicating that comorbidities do not influence therapy adherence [15] , or that specific comorbidities such as diabetes or depression are even associated with better adherence [9] .
In addition, prior chemotherapy and radiation appear to play a role in therapy adherence [13] [14] [15] [16] . Although both have been associated with better adherence in some analyses [14, 15] , other trials have reported that prior chemotherapy is associated with nonadherence [13, 16] .
The influence of tumor characteristics such as tumor size, stage, and grade has also been analyzed in some studies [15] [16] [17] 28] . Some investigators did not identify any association with nonadherence [15, 28] , whereas others described tumor stage or tumor size as risk factors [16, 17] . Some of the above patient and tumor characteristics were also investigated in the present analysis. Older age and the presence of comorbidities were confirmed as risk factors for non-persistence. Previous chemotherapy and radiotherapy, on the other hand, were not associated with premature treatment discontinuation in this study. Neither tumor grade [14, 17] nor BMI [7, 13] was found to have a significant association on therapy adherence in other analyses. In contrast to those trials, the present study identified both of these as predictors for non-persistence.
Since BMI has been associated with a lower incidence of arthralgia and musculoskeletal events in overweight but not obese women [32] , and the incidence of musculoskeletal burden is in turn associated with treatment discontinuation [13] , it is possible that a higher BMI is associated with a higher persistence with AI therapy. This is of special importance, since there have been several studies, which associated higher BMI with lower efficacy of antihormonal treatment [33] . At the time when the study was initiated, there were ongoing discussions on which patients should start with an AI as an initial therapy, which patients should switch, and which patients might be suitable for tamoxifen-only therapy [34] [35] [36] . Partly because of a different toxicity profile and due to the costs of the AIs at that time, there The persistence rate at 15 months is the proportion of patients with persistence (column 2) and the total number of patients with or without persistence. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group (grade); SD, standard deviation.
had to be specific reasons for patients to receive an AI initially. One of the reasons discussed was a high risk of recurrence. This might be reflected in a lower likelihood of non-persistence when the grade was high, as shown in the present analysis. The potential for recurrence might prompt patients and physicians to change behavioral patterns and this could be one reason for higher therapy persistence. The performance of the considered predictors was moderate in relation to the AUC as evaluation criteria. The fact that strong predictors in the sense of statistical significance often perform poor when applied to future patients is known from clinical studies as well as theoretical reflections [37, 38] . It is not surprising that the prediction performance of the final Cox model did not reach the performance of the full model because the selection process focused on finding strong predictors rather than optimizing the overall performance.
As patient recruitment took place at 278 sites, one strength of the present study is that it represents a broad population of BC patients. On the other hand, one weakness of the study is that persistence was evaluated by analyzing patients' questionnaires and assessments by the physicians treating them only at time of enrollment, after 6 and 12 months, and up to a maximum of 15 months. Since the recommended duration of endocrine treatment is at least 5 years and the study observation period was 1 year, it can be assumed that treatment persistence would even continue to decrease in subsequent years. However, it is the early persistence that is of more interest than the later one, especially because of its impact on patient's outcome. 
Conclusion
These results support the view that older patients with multimorbidity, a low tumor grade, and a low BMI are at the greatest risk for treatment discontinuation and might be able to benefit from programs promoting compliance and offering support. 
